Global Cannabis Valuation: Cash Flow Beats Tape Moves
Cannabis equities are again demonstrating why price action and valuation are not interchangeable. MJNA rose 100.00% on volume of 2,516,872, while CAN.AX fell 20.00% on volume of 8,020,165. Those moves are material as sentiment signals, particularly in thinly traded corners of the global universe, but they do not establish durable changes in business value. The more investable valuation question remains consistent across Canadian licensed producers, U.S.-listed cannabis-adjacent companies, European medical-cannabis platforms, and Australian operators: can reported operating progress convert into recurring cash flow without an expanding equity base?
The clearest filing-led framework comes from TLRY, even if it should be treated as a reference point rather than the center of a global cannabis allocation. Tilray’s fiscal 2026 results reported $915.454 million in net revenue and $61.139 million in adjusted EBITDA, yet free cash flow was negative $98.624 million. That spread captures the sector’s central valuation tension. Revenue diversification and adjusted EBITDA can support a strategic narrative, but neither alone proves that equity holders are accumulating per-share economic value.
For global investors, that distinction matters more than a single-session advance in CGC, CRON, ACB, SANT.DE, B8F.DE, or CAN.AX. The listed cannabis universe spans radically different regulatory regimes, currencies, liquidity profiles, capital structures, and end markets. Yet valuation discipline travels well: financial flexibility, cash conversion, dilution exposure, and evidence of sustainable margins are more portable analytical tools than headline-driven momentum.
The thesis: global cannabis is a cash-flow sorting exercise
The market currently offers a broad array of cannabis exposures, but not a uniform earnings framework. North American names can offer scale and liquidity, Canadian licensed producers provide international medical and consumer exposure, European listings offer a differentiated medical-cannabis policy read-through, and Australian securities can reflect a separate medical-market and small-cap risk profile. These categories should not be valued as if their regulatory pathways and financing options were interchangeable.
The sector-wide thesis is straightforward: valuation support should accrue to companies that can demonstrate a credible bridge from revenue and adjusted EBITDA to free cash flow, while maintaining discipline on share count and leverage. Companies that cannot provide that bridge may remain tradable on policy expectations, risk appetite, or local-market narratives, but their valuation case is inherently more contingent.
Tilray’s filing provides the most concrete evidence in the current fact set. In its SEC-filed fiscal 2026 earnings release, the company disclosed net revenue of $915.454 million, adjusted EBITDA of $61.139 million, and negative free cash flow of $98.624 million. It also issued fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million and stated that it expects more than $1 billion in annual revenue. The Tilray fiscal 2026 earnings release is therefore not simply an earnings document; it is a valuation test case for the wider cannabis complex.
An EBITDA-guidance increase matters. But without a management-provided reconciliation from adjusted EBITDA to GAAP profitability and free cash flow, investors should avoid assuming that an operating target automatically translates into equity-value accretion. The relevant forecast is conditional: if fiscal 2027 EBITDA falls within the stated range and cash consumption materially improves, the quality of the valuation debate improves. If EBITDA rises while free cash flow remains materially negative, the sector’s historic skepticism toward adjusted metrics will remain justified.
Dilution is the per-share valuation variable
The balance-sheet and share-count dimension is equally important. Tilray reported $225.977 million of cash and cash equivalents and $5.289 million of marketable securities at May 31, 2026. It also reported $8.775 million of bank indebtedness, $138.585 million of current and long-term debt, and $79.529 million of convertible debentures.
Those figures are not a standalone verdict on financial health. They are, however, essential inputs to a valuation process because the equity claim sits below debt and convertible obligations. More importantly, Tilray reported 131,683,075 common shares issued and outstanding, compared with 106,067,875 one year earlier after retrospective adjustment for the reverse split. That increase sharpens the question for every cannabis equity with a capital need: are new shares financing growth that expands future per-share cash-flow capacity, or merely extending the runway?
The fiscal 2026 SEC filing makes the analytical hierarchy clear. Investors should begin with cash, debt, convertibles, and share count before applying any revenue or EBITDA multiple. In cannabis, the nominal enterprise-growth story can look compelling while the per-share economics remain unproven.
This is particularly relevant when comparing CGC, CRON, and ACB with more regionally focused securities. Canadian LPs are often analyzed through their capacity to access international medical markets, consumer brands, and diversified product categories. But cross-border optionality still requires a capital structure that preserves shareholder participation in eventual cash generation. A valuation process that gives full credit for global optionality but limited attention to dilution can overstate the benefit of that optionality.
Europe offers a different policy and valuation read-through
Europe should not be treated as a derivative of the U.S. federal-policy debate. European-listed operators such as SANT.DE and B8F.DE trade against a separate mix of medical-market development, country-specific regulation, local distribution capabilities, and exchange liquidity. Their market behavior can therefore diverge from Canadian LPs and U.S.-listed cannabis-adjacent companies even when global risk appetite is moving in the same direction.
In the current tape, SANT.DE rose 6.21% and B8F.DE rose 1.45%. Those changes are modest compared with the extreme move in MJNA, but that is precisely the point: the relative signal from European names may be more about localized positioning than about a global cannabis rerating. Neither move supplies enough evidence to support a valuation conclusion on its own. Investors need issuer-specific disclosures on revenue quality, cash requirements, margins, and capital needs before equating a positive session with a lower risk premium.
The European comparison also reinforces why U.S. regulatory catalysts should be compartmentalized. The DEA’s marijuana-rescheduling hearing occurred from June 29 through July 15, and the administrative law judge set August 17 as the deadline for proposed transcript corrections and post-hearing briefs. The DEA order on transcript corrections and post-hearing briefs does not establish a final regulatory outcome. It establishes that timing remains uncertain.
That uncertainty is most direct for U.S.-linked valuation narratives, but it also affects global capital flows. A favorable U.S. outcome could increase risk appetite across the listed cannabis ecosystem, including Canadian and European names. A delayed or unfavorable process could have the opposite effect. Still, European companies should ultimately be valued on their own local regulatory access and operating execution, not on an assumed correlation with U.S. policy.
Macro matters, but this package does not support a macro call
No macro data are available in the current package. As a result, there is no evidence-based basis to make a directional claim on rates, the U.S. dollar, or broad risk appetite. That limitation matters because global cannabis equities are unusually sensitive to external financing conditions and small-cap liquidity.
The differentiated impact is nevertheless conceptually clear. A shift in global risk appetite can affect U.S.-listed names, Canadian LPs, German-listed securities, and ASX-listed companies through different channels: investor flows, currency translation, financing appetite, and local exchange liquidity. But the absence of verified macro prints means investors should resist assigning today’s moves to a specific rates or dollar narrative.
Instead, the tape should be read as fragmented. AVCN.TO gained 11.26%, RVV.V declined 15.25%, BOT.AX gained 5.56%, and WHC.AX declined 14.29%. These outcomes show that global cannabis and cannabis-adjacent equities are not trading as a single macro basket. They are a collection of company-specific, jurisdiction-specific, and liquidity-specific exposures.
What would change the valuation debate
The strongest positive development for the sector would be credible evidence that adjusted EBITDA is converting into free cash flow without material dilution. For Tilray, that means fiscal 2027 delivery within or above its stated $68 million to $75 million adjusted EBITDA range, alongside a demonstrable improvement in cash consumption. It would also mean clearer disclosure around the earnings contribution and cash economics of the beverage platform.
Tilray described BrewDog as supporting a pro forma global beverage platform of approximately $500 million and earlier described an acquisition price of approximately £40 million in cash. The company also described a Carlsberg partnership beginning in 2027. The SEC-filed release discussing BrewDog gives investors a specific strategic marker, but not yet a quantified profitability bridge. That distinction is crucial: acquisition scale is not the same as acquisition value creation.
The principal risks are equally concrete. Free cash flow may remain negative despite EBITDA growth. The share count may continue to rise without a proportional expansion in per-share cash-flow capacity. Integration may not yield disclosed profitability or cash improvement. Finally, cannabis and beverage competition—including illicit-market participants and larger, well-capitalized competitors—can pressure the path from revenue to durable cash generation, as described in Tilray’s fiscal 2026 Form 10-K.
Bottom line
Global cannabis valuation should be approached as a cash conversion and capital-structure screen, not a momentum screen. The move in MJNA, the decline in CAN.AX, and the divergent trading in SANT.DE, B8F.DE, AVCN.TO, and BOT.AX confirm that the universe is fragmented across jurisdictions and liquidity pools.
For positioning, we would lean toward monitoring issuers that can document improving free cash flow, stable or disciplined share counts, and transparent operating bridges across cannabis, distribution, and adjacent businesses. What we would watch most closely is whether fiscal 2027 disclosures—starting with TLRY as the best-documented current reference case—show that higher adjusted EBITDA is becoming cash available to equity holders rather than another reason to defer the valuation reckoning.